As deficiency in MRAP2 partly affects the MC4R pathway, the subsequent energy homeostasis dysregulation and obesity in MRAP2-deficient subjects might be theoretically improved by an MC4R-agonist treatment (25). This evidence concerns the gene MC4R and obesity due to melanocortin 4 receptor deficiency.